GLP-1 receptor agonists safely improved blood sugar, weight, and cholesterol in 68 liver transplant patients with diabetes, enabling 45.5% of insulin-dependent patients to stop insulin entirely by 18 months.
45.5% stopped insulin by 18 monthsAmong 45 liver transplant patients requiring insulin when GLP-1 RA therapy was added, nearly half were able to discontinue insulin entirely by 18 months — a dramatic improvement in treatment burden for this medically complex population.
What the researchers found
In 68 liver transplant recipients with diabetes, GLP-1 receptor agonist therapy added to metformin or insulin significantly reduced fasting glucose, HbA1c, weight, BMI, waist circumference, and total/LDL cholesterol over 18 months. Liver stiffness decreased during the first 6 months. Among 45 patients on insulin at baseline, 33.2% stopped insulin by 6 months and 45.5% by 18 months. Adverse events were low: 26.9% mild nausea, 7.69% discontinued due to GI intolerance. No pancreatitis episodes occurred despite concurrent calcineurin inhibitors, and no immunosuppressant adjustments were needed.
Why it matters
Liver transplant recipients frequently develop diabetes (post-transplant diabetes or worsening pre-existing diabetes), but clinicians have been reluctant to use GLP-1 receptor agonists in these patients due to lack of safety data — particularly concerns about pancreatitis risk when combined with immunosuppressive drugs like calcineurin inhibitors. This study provides the first substantial evidence that GLP-1 RAs are both safe and effective in this population, with no drug interactions and a remarkable rate of insulin discontinuation.
How the study worked
Prospective observational study of 68 liver transplant recipients with diabetes who started GLP-1 RA therapy added to metformin or insulin. Patients were evaluated at baseline and at 6, 12, and 18 months. Assessments included glycemic control (fasting glucose, HbA1c), body composition (weight, BMI, waist circumference via bio-impedance analysis), liver health (stiffness and steatosis via transient elastography), pancreatic safety (amylase, lipase), and adverse event reporting via email contact.
Who was studied
68 liver transplant recipients with diabetes, evaluated over 18 months on GLP-1 receptor agonist therapy
What this study cannot tell us
This is an observational study without a control group, so improvements cannot be definitively attributed to GLP-1 RA therapy alone. The 68-patient sample is relatively small. Follow-up of 18 months is insufficient to assess long-term complications. The specific GLP-1 RA agents and doses used are not detailed in the abstract. The study did not assess hard outcomes like cardiovascular events, renal impairment, or mortality.
How to read the evidence
This is a prospective observational study without a control group, which limits causal attribution. However, it provides the first substantial real-world evidence for GLP-1 RA use in liver transplant recipients — a population systematically excluded from randomized clinical trials of these drugs. The multi-timepoint assessment and comprehensive safety monitoring strengthen the findings.
When this study was published
Published in 2025, this is among the first studies to specifically evaluate GLP-1 receptor agonists in liver transplant recipients, addressing an urgent clinical evidence gap as these drugs become increasingly prescribed.
The bigger picture
Post-transplant diabetes is extremely common and significantly worsens outcomes for transplant recipients. This study fills an important evidence gap by demonstrating that GLP-1 receptor agonists can be safely used in this complex patient population. The finding that no immunosuppressant adjustments were needed is particularly reassuring, as drug interactions are a constant concern in transplant medicine. As GLP-1 RAs continue to demonstrate benefits across diverse patient populations, this extends their potential reach to one of the most medically complex groups.
Questions still open
- Do the benefits of GLP-1 RAs in liver transplant recipients persist beyond 18 months, and do they translate into reduced cardiovascular events or improved graft survival?
- Which specific GLP-1 receptor agonists are most suitable for transplant recipients on calcineurin inhibitors?
- Could GLP-1 RA therapy started early after liver transplant prevent the development of post-transplant diabetes?
Common questions
Why haven't GLP-1 drugs been used in transplant patients before?
How significant is it that nearly half of patients stopped needing insulin?
Read the original research
Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors.
Frontiers in endocrinology, 16, 1586941
Citation
Grancini, Valeria; Cogliati, Irene; Alicandro, Gianfranco; Oliverio, Andreina; Di Benedetto, Clara; Gaglio, Alessia; Lampertico, Pietro; Resi, Veronica; Orsi, Emanuela. (2025). Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors.. Frontiers in endocrinology, 16, 1586941. https://doi.org/10.3389/fendo.2025.1586941